TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age above 18 years.~2. Chronically infected with HCV genotype 4.~3. Treatment naïve.~4. No advanced fibrosis. Defined by the absence of clinical, radiological and laboratory signs of cirrhosis, and fibrosis assessment consistent with fibrosis stage (Metavir F2) or less by liver biopsy or transient elastography.~5. Not expected to leave the country for six months after the end of the intervention.~Exclusion Criteria:~1. Incapability of providing an informed consent to participate in the study.~2. Advanced fibrosis (Metavir F3) or cirrhosis (Metavir F4).~3. HIV or HBV co-infection~4. Organ transplant recipients.~5. Type 2 or 3 cryoglobulinemia with end-organ manifestations.~6. Proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis~7. Patients with a higher risk of transmitting the disease (Dialysis patients, incarcerated individuals, and intravenous drug abusers).~8. The use of any medication that has major interactions with Elbasvir or Grazoprevir as defined by the University of Liverpool drug interaction database, and cannot be discontinued or replaced with other alternatives.~9. Pregnancy.~10. History of hepatocellular carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Elbasvir, Grazoprevir 50-100Mg Oral Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dementia Caregiver Chronic Grief Management: A Live Online Video Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21 years of age or older~* Identified as family member, fictive kin (self-identified family member), or partner of care recipient at any time post permanent placement of care in long-term care facility (LTCF)~* Care recipient has a documented ADRD diagnosis and resides in any type of unit in a LTCF~* Possessing self-reported basic computer literacy and in-home internet access~* Able to speak, read, and write English~* Not currently attending another ADRD caregiver grief management group~* Experiencing high to moderate levels of grief per screening with the Marwit-Meuser Caregiver Grief Inventory-Short Form (MMCGI-SF) (70 and above); and/or~* Experiencing high levels of depressive symptoms per screening with Patient Health Questionnaire-9 (PHQ-9) (scores 10 and above)~Exclusion Criteria:~* Non English speaker, reader, writer~* Scoring under the cut off points on the MM-CGI-SF and the PHQ-9~* Reporting no basic computer literacy; no internet access

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CGMI-V (Type: EXPERIMENTAL): Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
- Minimal Treatment (MT) (Type: NO_INTERVENTION): Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian women aged 18 years and older with proven HPV-associated CIN 2/3~* Colposcopy with fully visible transformation zone and lesion~* Safe Contraception~* Signed Informed Consent~* Negative urine pregnancy test~* Able to communicate well with the investigator, to understand and comply with the requirements of the study~* Signed the written informed consent~Exclusion Criteria:~* Women who are pregnant or lactating or become pregnant during the conduct of the study~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* History of hypersensitivity to the trial drug or to drugs with a similar chemical structure~* Participating in another clinical trial within 30 days~* Malignancy~* Immunosuppression (medication, illness)~* HIV- or Hepatitis infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Imiquimod (Type: ACTIVE_COMPARATOR): topical therapy for 16 weeks with imiquimod containing therapy
- Placebo (Type: PLACEBO_COMPARATOR): topical therapy for 16 weeks with a placebo containing vaginal suppository

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19\~50 years old, healthy male volunteers~* \>55Kg(Body weight) and 18.5\<BMI\<28~Exclusion Criteria:~* AST or ALT \> 3 \* Upper normal range (Lab)~* Total bilirubin \> 2.0 mg/dl~* Systolic BP \>140 OR \<90, Diastolic BP \>100 OR \<60

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- YHD1119 (Type: EXPERIMENTAL): Pregabalin 300mg
- Lyrica (Type: ACTIVE_COMPARATOR): Pregabalin 150mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled for upper endoscopy and agree to the terms of fast track offer.~Exclusion Criteria:~* If a patient expresses concern about service denial, confusion about the bargain, or refuses to participate, the investigators will schedule these patients routinely.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fast-tracked (Type: EXPERIMENTAL): 'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots.
- Control (Type: NO_INTERVENTION): Patients who are scheduled routinely

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥50 years with DM2 and symptomatic PAD diagnosed clinically (according to Fontaine criteria, stage IIa or IIb and III) and by measuring the ΑΒΙ.~Exclusion Criteria:~* Congestive heart failure, history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular extrasystoles or QTc prolongation.~* Patients with atrial fibrillation taking any anticoagulant therapy or patients with a history of cardioembolic ischemic stroke or hemorrhagic stroke.~* Patients with a history (≤ 12 months) of acute coronary syndrome receiving dual antiplatelet therapy, or patients receiving monotherapy with aspirin.~* Patients with hepatic impairment (child-Pugh staging, calibration ≥ 5) or renal impairment (creatinine clearance ≤ 30ml / min), recent peptic ulcer, a history of hypersensitivity to cilostazol, cancer patients undergoing treatment.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 75 mg/day
- Clopidogrel plus cilostazol (Type: ACTIVE_COMPARATOR): Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Severe persistent asthma with the following characteristics:~* Uncontrolled according to Global Initiative for Asthma (GINA) 2007 guidelines and at least 2 exacerbations having required systemic corticosteroid and/or at least 1 hospitalization or emergency room visit in the past year.~* Treated with high-dose inhaled corticosteroid (i.e. \> 1,000 µg beclometasone dipropionate equivalent per day) plus inhaled long-acting β2 agonist (with or without maintenance oral corticosteroid).~* Non-atopic, i.e. negative blood multiallergic testing and negative Aspergillus-specific IgE-radio allergosorbent blood test and negative skin prick tests to a battery of common aeroallergens~Exclusion Criteria:~* Current smokers or smoking history stopped for less than 3 years or \> 10 pack years.~* Asthma exacerbation during the 4 weeks prior to randomization.~* Active lung disease other than non-atopic asthma.~* Patients with an active cancer, a suspicion of cancer or any history of cancer with less than 5 disease free years.~* Pregnant or nursing (lactating) women.~* Treatment with omalizumab.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of advanced non-small cell lung cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Any prior treatment for non-small cell lung cancer~* Brain metastases~* With diabetes

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- CP-751,871 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LowCostomy: Dedicated Toward Creating a High-quality, Low-cost Colostomy Appliance for Those in Sub-Saharan Africa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults with age +/\>18 years~* Recruited from Duke University~* Local community members~Exclusion Criteria:~* Any pre-existing skin conditions~* Skin allergies to tegaderm or other adhesive products contained within the study and control rings

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tanzanian beeswax-pine adhesive (Type: EXPERIMENTAL): Each study subject will be tested with a thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
- Domestic beeswax-pine adhesive (Type: ACTIVE_COMPARATOR): Each study subject will be tested with a thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
- Control (Type: ACTIVE_COMPARATOR): Each study subject will be tested with a thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, age 18 years or older~* Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic, accelerated, or blast phase~* Patients will have either failed, demonstrated intolerance, or a combination of prior failure and intolerance, to prior treatments with at least two tyrosine kinase inhibitors (TKI's). Failure of TKI treatment may either be primary (never achieved a response) or secondary resistance (loss of response).~* Acceptable Renal and Liver Function~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~* Sexually active patients and their partners must use an effective double barrier method of contraception~Exclusion Criteria:~* New York Heart Association classification (NYHA) class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition~* Myocardial infarction in the previous 12 weeks.~* Other concurrent illness which would preclude study conduct and assessment~* uncontrolled and active infection, and positive HIV or positive HTLV I/II status, whether on treatment or not.~* Pregnant or lactating.~* Any medical or psychiatric condition, which may compromise the ability to give written informed consent or to comply with the study protocol.~* Lymphoid Ph+ blast crisis~* Patient is enrolled in another clinical investigation within 30 days of enrollment or is receiving another investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OMA (Type: EXPERIMENTAL): Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.~Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination With PD-L1 Peptide Against Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically verified multiple myeloma~2. Newly treated with HDT and no signs of relapse~3. Age ≥18 years~4. Performance status ≤ 2 (ECOG-scale)~5. Expected survival \> 3 months~6. Sufficiently regenerated bone marrow function, i.e.~   1. Leucocytes ≥ 1,5 x 109~  2. Granulocytes ≥ 1,0 x 109~  3. Thrombocytes ≥ 20 x 109~7. Creatinine \< 2.5 upper normal limit, i.e. \< 300 μmol/l~8. Sufficient liver function, i.e.~   1. ALAT \< 2.5 upper normal limit, i.e. ALAT \<112 U/l~  2. Bilirubin \< 30 U/l~9. Women agreement to use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 120 days after the last treatment.~10. For men: agreement to use contraceptive measures and agreement to refrain from donating sperm.~Exclusion Criteria:~1. Non-secretory myeloma~2. Other malignancies in the medical history excluding squamous cell carcinoma of the skin and patients cured for another malignant disease with no sign of relapse three years after ended treatment.~3. Significant medical condition per investigators judgement e.g. severe Asthma/COPD, poorly regulated heart condition, insulin dependent diabetes mellitus.~4. Acute or chronic viral infection e.g. HIV, hepatitis or tuberculosis~5. Serious known allergies or earlier anaphylactic reactions.~6. Known sensibility towards Montanide ISA-51~7. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.~8. Pregnant and breastfeeding women.~9. Fertile women not using secure contraception with a failure rate less than \< 1%~10. Patients taking immune suppressive medications incl. corticosteroids and methotrexate at the time of enrollment~11. Psychiatric disorders that per investigator judgment could influence compliance.~12. Treatment with other experimental drugs~13. Treatment with other anti-cancer drugs - except bisphosphonates and denosumab~14. Patients with active uncontrolled hypercalcemia~15. Patients who have received chemotherapy, immune therapy, radiation therapy within the last 28 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccination (Type: EXPERIMENTAL): Vaccine: PD-L1 peptide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged ≥18 years with physician diagnosis of atopic dermatitis for \>1 year as defined by American Academy of Dermatology Consensus Criteria.~* Atopic dermatitis involvement of ≥10% of body surface area at screening and baseline.~* EASI score of ≥12 at screening or ≥16 at baseline.~* IGA score of ≥3 at screening and baseline (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe)~* Baseline Pruritus Numerical Rating Scale (NRS) score for maximum itch intensity ≥3 over the previous 24 hours.~Exclusion Criteria:~* Pregnant or lactating women.~* Prior treatment with ISB 830~* Treatment with biologics~* Systemic corticosteroids, immunosuppressive/immunomodulatory drugs or phototherapy within 4 weeks of baseline~* Active chronic or acute infection requiring systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISB 830 - Part 1 Group 1 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
- ISB 830 - Part 1 Group 2 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
- ISB 830 - Part 1 Group 3 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
- Placebo - Part 1 Group 4 (Type: PLACEBO_COMPARATOR): Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
- ISB 830 - Part 2 Group 5 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
- Placebo - Part 2 Group 6 (Type: PLACEBO_COMPARATOR): Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years.~* Patients with hepatocellular carcinoma (BCLC, stageB/C) proved by histopathology or proved by CT or MRI imaging system, relapsed after previous therapy and no effective therapies known at this time.~* Life expectancy of ≥ 12 weeks.~* WBC\>3.0×10\^9/L, LYMPH\> 0.8×10\^9/L, Hb\>85g/L, PLT\>50×10\^9/L, Cre\<1.5×the upper limit of normal value.~* iNKT\>10 cell/mL in peripheral blood mononuclear cell (PBMC).~* Able to understand and sign the informed consent.~Exclusion Criteria:~* Any uncontrolled systematic disease: hypertension, heart disease, and et al.;~* Portal vein tumor thrombus, central nervous system tumor metastasis, or combined with other tumors;~* Receiving radiochemotherapy, local therapy, or targeting drugs within 4 weeks prior to this treatment;~* Unstable immune systematic diseases or infectious diseases;~* Combined with AIDS or syphilis;~* Patients with history of stem cell or organ transplantation;~* Patients with allergic history to related drugs and immunotherapy;~* Patients with complications associated with liver diseases: moderate or severe pleural effusion, pericardial effusion, ascites, or gastrointestinal hemorrhage;~* Pregnant or lactating subjects;~* Unsuitable subjects considered by clinicians.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TAE/TACE+iNKT for unresectable HCC (Type: EXPERIMENTAL): TAE/TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TAE/TACE will be performed at 0th and 4th week. 5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
- TAE/TACE for unresectable HCC (Type: OTHER): TAE/TACE will be conducted at 0th week and 4th week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete